Sophiris Bio (SPHS) Issues Quarterly Earnings Results, Misses Expectations By $0.02 EPS

Sophiris Bio (NASDAQ:SPHS) issued its earnings results on Wednesday. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.11) by ($0.02), Bloomberg Earnings reports.

Sophiris Bio stock traded down $0.02 during mid-day trading on Thursday, reaching $2.14. 80,102 shares of the company’s stock were exchanged, compared to its average volume of 196,809. The company has a current ratio of 13.37, a quick ratio of 13.37 and a debt-to-equity ratio of 0.60. Sophiris Bio has a 12 month low of $1.80 and a 12 month high of $2.95. The firm has a market capitalization of $64.44, a PE ratio of -11.89 and a beta of 1.30.

How to Become a New Pot Stock Millionaire

A hedge fund recently raised its stake in Sophiris Bio stock. Vanguard Group Inc. lifted its holdings in shares of Sophiris Bio Inc (NASDAQ:SPHS) by 1.0% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 731,437 shares of the biopharmaceutical company’s stock after acquiring an additional 7,600 shares during the period. Vanguard Group Inc. owned 2.43% of Sophiris Bio worth $1,609,000 at the end of the most recent reporting period. 6.37% of the stock is owned by institutional investors and hedge funds.

SPHS has been the topic of several analyst reports. Maxim Group reaffirmed a “buy” rating and issued a $5.00 target price (down previously from $6.00) on shares of Sophiris Bio in a report on Wednesday, February 14th. ValuEngine raised shares of Sophiris Bio from a “strong sell” rating to a “sell” rating in a report on Friday, December 15th. Finally, HC Wainwright set a $6.00 price objective on shares of Sophiris Bio and gave the stock a “buy” rating in a report on Wednesday, January 17th. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $6.00.

COPYRIGHT VIOLATION NOTICE: “Sophiris Bio (SPHS) Issues Quarterly Earnings Results, Misses Expectations By $0.02 EPS” was originally reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The correct version of this piece of content can be viewed at https://www.chaffeybreeze.com/2018/03/23/sophiris-bio-sphs-issues-quarterly-earnings-results-misses-expectations-by-0-02-eps.html.

About Sophiris Bio

Sophiris Bio, Inc, formerly Protox Therapeutics Inc, is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate).

Earnings History for Sophiris Bio (NASDAQ:SPHS)

Receive News & Ratings for Sophiris Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sophiris Bio and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply